Codman Neuro to Distribute Pulsar Vascular's PulseRider in Europe

September 5, 2014—Codman Neuro, part of DePuy Synthes Companies of Johnson & Johnson, announced it has reached an exclusive distribution agreement with Pulsar Vascular to market and promote that company’s PulseRider in Europe, the Middle East, and Africa. Pulsar Vascular developed the PulseRider, which is a minimally invasive self-expanding nitinol implant intended for use with embolic coils in the treatment of unruptured wide-neck intracranial aneurysms originating on or near a bifurcation, to bridge the neck of cerebral aneurysms. The agreement was entered into by one of Codman Neuro’s European Union-affiliated companies.

The PulseRider device received initial CE Mark approval in Europe in late 2013. In the United States, the device is limited to investigational use only and has not been approved by the US Food and Drug Administration (FDA) for distribution, advised Codman Neuro.

In the announcement, Professor Monika Killer-Oberpfalzer, MD, of Paracelsus Medical University in Salzburg, Austria, commented, “Repairing wide-neck intracranial aneurysms is a challenging endovascular procedure, and treatment options are extremely limited. We welcome technology specifically designed to enhance our ability to treat these complex aneurysms more easily with less risk in the hope that more lives can be saved.”